Research and Markets: Global Gastrointestinal Disorders Drug Pipeline Capsule - 2012

Research and Markets: Global Gastrointestinal Disorders Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Gastrointestinal Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global gastrointestinal drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Colorectal Cancer, Crohn's Disease, Esophageal Cancer, Gastrointestinal Stromal Tumors, Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, Pancreatic Cancer, and Ulcerative Colitis.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Gastrointestinal Disorders Drug Pipeline Insights

- Colorectal Cancer Drug Pipeline Insights

- Crohn's Disease Drug Pipeline Insights

- Esophageal Cancer Drug Pipeline Insights

- Gastrointestinal cancer Drug Pipeline Insights

- Gastrointestinal Stromal Tumors Drug Pipeline Insights

- Gastroesophageal Reflux Disease Drug Pipeline Insights

- Irritable Bowel Syndrome Drug Pipeline Insights

- Pancreatic Cancer Drug Pipeline Insights

- Ulcerative Colitis Drug Pipeline Insights

Suggested Articles

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.